– USA, CA – āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, announced the appointment of Dipal Doshi to its Board of Directors.
About Dipal Doshi
Dipal Doshi serves as CEO of Entrada Therapeutics (NASDAQ: TRDA).
“I am honored to join āshibio’s Board as the company continues to advance its novel therapeutic pipeline,” said Dipal Doshi. “āshibio’s strong focus on bone and connective tissue disorders that have no approved treatments, or where the treatment options are inadequate, fills an important gap in rare disease drug development. Pankaj and his team have the experience and support to deliver for these patients and their families, including those living with FOP, and I am looking forward to helping them succeed.”
Dipal Doshi is CEO of Entrada Therapeutics and a Member of its Board of Directors. He previously served as President and CEO from 2017 to 2023. He has led many critical functions in biotechnology and pharmaceutical companies, including roles focused on business development, corporate strategy, new product planning, commercial planning, and finance. Prior to joining Entrada, Dipal was CBO at Amicus Therapeutics, a global biotechnology company focused on rare diseases. He has also held senior level positions at a healthcare private equity fund and Catalent. Earlier in his career, Dipal Doshi worked in Merrill Lynch’s Investment Banking Group and held several roles at Eli Lilly and Company.
Dipal Doshi holds an MBA from The Wharton School of the University of Pennsylvania and a BA from Rutgers University. Dipal is a Fellow of the Aspen Institute and on the Board of Advisors of Life Science Cares Boston.
About āshibio
āshibio is a privately held, clinical-stage biotechnology company developing a pipeline of novel therapeutics for the treatment of bone and connective tissue disorders. Founded in 2022 by company CEO Pankaj Bhargava, M.D., and the team at MPM BioImpact, āshibio exited stealth mode in June 2024 with $40 million in Seed and Series A financing. The company plans to initiate a Phase 2/3 trial of its lead asset, andecaliximab, in the second half of 2024 in patients with fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder characterized by progressive heterotopic ossification (HO), a pathological condition characterized by abnormal bone formation in muscle and soft tissues.
For more information: https://ashibio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.